Stock Track | Tempus AI Soars 5.11% Intraday on New Oncology Service and Collaboration Announcements

Stock Track04-15

Tempus AI's stock soared 5.11% during intraday trading on Wednesday.

The surge follows the company's announcement of a new automated clinical update service designed to keep cancer therapy recommendations aligned with current guidelines without requiring new patient samples. Tempus AI also reported that 31 research abstracts have been accepted for presentation at the AACR 2026 conference, highlighting its expanding research footprint in AI-powered oncology.

In a separate development, Tempus AI entered into a collaboration with Predicta Biosciences to commercially expand access to an ultrasensitive whole-genome sequencing assay for hematologic cancers. The co-branded GenoPredicta assay aims to improve diagnosis and monitoring while reducing the need for invasive biopsies, representing a strategic expansion of the company's diagnostic offerings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142434330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142434330","market":"sg","top_or_hot":-1,"title":"Stock Track | Tempus AI Soars 5.11% Intraday on New Oncology Service and Collaboration Announcements","media":"Stock Track","content":"<p>Tempus AI's stock soared 5.11% during intraday trading on Wednesday.</p><p>The surge follows the company's announcement of a new automated clinical update service designed to keep cancer therapy recommendations aligned with current guidelines without requiring new patient samples. Tempus AI also reported that 31 research abstracts have been accepted for presentation at the AACR 2026 conference, highlighting its expanding research footprint in AI-powered oncology.</p><p>In a separate development, Tempus AI entered into a collaboration with Predicta Biosciences to commercially expand access to an ultrasensitive whole-genome sequencing assay for hematologic cancers. The co-branded GenoPredicta assay aims to improve diagnosis and monitoring while reducing the need for invasive biopsies, representing a strategic expansion of the company's diagnostic offerings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tempus AI Soars 5.11% Intraday on New Oncology Service and Collaboration Announcements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tempus AI Soars 5.11% Intraday on New Oncology Service and Collaboration Announcements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tempus AI's stock soared 5.11% during intraday trading on Wednesday.</p><p>The surge follows the company's announcement of a new automated clinical update service designed to keep cancer therapy recommendations aligned with current guidelines without requiring new patient samples. Tempus AI also reported that 31 research abstracts have been accepted for presentation at the AACR 2026 conference, highlighting its expanding research footprint in AI-powered oncology.</p><p>In a separate development, Tempus AI entered into a collaboration with Predicta Biosciences to commercially expand access to an ultrasensitive whole-genome sequencing assay for hematologic cancers. The co-branded GenoPredicta assay aims to improve diagnosis and monitoring while reducing the need for invasive biopsies, representing a strategic expansion of the company's diagnostic offerings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1142434330","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142434330","pubTimestamp":1776260526,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tempus AI's stock soared 5.11% during intraday trading on Wednesday.The surge follows the company's announcement of a new automated clinical update service designed to keep cancer therapy...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"个股赛道|腾邦AI盘中大涨5.11%，因新的肿瘤服务和合作公告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"Tempus AI's stock soared 5.11% during intraday trading on Wednesday.The surge follows the company's announcement of a new automated clinical update service designed to keep cancer therapy recommendations aligned with current guidelines without requiring new patient samples. Tempus AI also reported that 31 research abstracts have been accepted for presentation at the AACR 2026 conference, highlighting its expanding research footprint in AI-powered oncology.In a separate development, Tempus AI entered into a collaboration with Predicta Biosciences to commercially expand access to an ultrasensitive whole-genome sequencing assay for hematologic cancers. The co-branded GenoPredicta assay aims to improve diagnosis and monitoring while reducing the need for invasive biopsies, representing a strategic expansion of the company's diagnostic offerings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142434330","isCrawlerRequest":true}